Genetic Association Studies in Epilepsy Pharmacogenomics: Lessons Learnt and Potential Applications

• Shorvon SD : The treatment of epilepsy. Blackwell Publishers, Oxford, UK (2004).
   Google Scholar
• Tate SK , DepondtC, SisodiyaSM et al.: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA102(15), 5507–5512 (2005).
   PubMed Web of Science ®Google Scholar
• Devinsky O : Patients with refractory seizures.N. Engl. J. Med.340(20), 1565–1570 (1999).
   PubMed Web of Science ®Google Scholar
• Blum M , DemierreA, GrantDM, HeimM, MeyerUA: Molecular mechanism of slow acetylation of drugs and carcinogens in humans.Proc. Natl Acad. Sci. USA88(12), 5237–5241 (1991).
   PubMed Web of Science ®Google Scholar
• Vatsis KP , MartellKJ, WeberWW: Diverse point mutations in the human gene for polymorphic N-acetyltransferase.Proc. Natl Acad. Sci. USA88(14), 6333–6337 (1991).
   PubMed Web of Science ®Google Scholar
• Krynetski EY , SchuetzJD, GalpinAJ, Pui CH, Relling MV, Evans WE: A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA92(4), 949–953 (1995).
   PubMed Web of Science ®Google Scholar
• Phillips HA , SchefferIE, CrosslandKM et al.: Autosomal dominant nocturnal frontal-lobe epilepsy, genetic heterogeneity and evidence for a second locus at 15q24. Am. J. Hum. Genet.63(4), 1108–1116 (1998).
   PubMed Web of Science ®Google Scholar
• Kwan P , BrodieMJ: Early identification of refractory epilepsy.N. Engl. J. Med.342(5), 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Sander JW : The natural history of epilepsy in the era of new antiepileptic drugs and surgical treatment.Epilepsia44(Suppl. 1), 17–20 (2003).
   PubMedGoogle Scholar
• Lynch BA , LambengN, NockaK et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl Acad. Sci. USA101(26), 9861–9866 (2004).
   PubMed Web of Science ®Google Scholar
• Meldrum BS : Update on the mechanism of action of antiepileptic drugs.Epilepsia37(Suppl. 6), S4–S11 (1996).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM : Mechanisms of antiepileptic drug resistance.Curr. Opin. Neurol.16(2), 197–201 (2003).
   PubMed Web of Science ®Google Scholar
• Schinkel AH : Pharmacological insights from P-glycoprotein knockout mice.Int. J. Clin. Pharmacol. Ther.36(1), 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• Seetharaman S , BarrandMA, MaskellL, ScheperRJ: Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates.J. Neurochem.70(3), 1151–1159 (1998).
   PubMed Web of Science ®Google Scholar
• Licinio J , Wong M-L: Pharmacogenomics. The Search for Individualized Therapies. Wiley-VCH, Weinheim, Germany (2002).
   Google Scholar
• Loscher W , PotschkaH: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.J. Pharmacol. Exp. Ther.301(1), 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Lazarowski A , SevleverG, TaratutoA, MassaroM, RabinowiczA: Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy.Pediatr. Neurol.21(4), 731–734 (1999).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM , HeffernanJ, SquierMV: Overexpression of P-glycoprotein in malformations of cortical development.Neuroreport10(16), 3437–3441 (1999).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM , LinWR, HardingBN, Squier MV, Thom M: Drug resistance in epilepsy, expression of drug resistance proteins in common causes of refractory epilepsy. Brain125(Pt 1), 22–31 (2002).
   PubMed Web of Science ®Google Scholar
• Tishler DM , WeinbergKI, HintonDR, BarbaroN, AnnettGM, RaffelC: MDR1 gene expression in brain of patients with medically intractable epilepsy.Epilepsia36(1), 1–6 (1995).
   PubMed Web of Science ®Google Scholar
• Dombrowski SM , DesaiSY, MarroniM et al.: Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia42(12), 1501–1506 (2001).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM , LinWR, SquierMV, Thom M: Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet357(9249), 42–43 (2001).
   PubMed Web of Science ®Google Scholar
• Potschka H , BaltesS, LoscherW: Inhibition of multidrug transporters by verapamil or probenecid does not alter blood–brain barrier penetration of levetiracetam in rats.Epilepsy Res.58(2–3), 85–91 (2004).
   PubMed Web of Science ®Google Scholar
• Sisodiya SM , MartinianL, SchefferGL et al.: Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia44(11), 1388–1396 (2003).
   PubMed Web of Science ®Google Scholar
• Aronica E , GorterJA, van Vliet EA et al.: Overexpression of the human major vault protein in gangliogliomas. Epilepsia44(9), 1166–1175 (2003).
   PubMed Web of Science ®Google Scholar
• Awasthi S, H allene KL, Fazio V: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci.6, 61 (2005).
   Google Scholar
• Rizzi M , CacciaS, GuisoG et al.: Limbic seizures induce P-glycoprotein in rodent brain, functional implications for pharmacoresistance. J. Neurosci.22(14), 5833–5839 (2002).
   PubMed Web of Science ®Google Scholar
• Seegers U , PotschkaH, LoscherW: Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy.Epilepsy Res.51(3), 257–268 (2002).
   PubMed Web of Science ®Google Scholar
• Seegers U , PotschkaH, LoscherW: Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions.Eur. J. Pharmacol.451(2), 149–155 (2002).
   PubMed Web of Science ®Google Scholar
• Schuetz EG , SchinkelAH, RellingMV, SchuetzJD: P-glycoprotein, a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.Proc. Natl Acad. Sci. USA93(9), 4001–4005 (1996).
   PubMed Web of Science ®Google Scholar
• Volk HA , LoscherW: Multidrug resistance in epilepsy, rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.Brain128(Pt 6), 1358–1368 (2005).
   PubMed Web of Science ®Google Scholar
• Park BK , PirmohamedM, Kitteringham NR: The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol. Ther.68(3), 385–424 (1995).
   PubMed Web of Science ®Google Scholar
• Patsalos PN , FroscherW, PisaniF, van Rijn CM: The importance of drug interactions in epilepsy therapy. Epilepsia43(4), 365–385 (2002).
   PubMed Web of Science ®Google Scholar
• Daly AK : Pharmacogenetics of the major polymorphic metabolizing enzymes.Fundam. Clin. Pharmacol.17(1), 27–41 (2003).
   PubMed Web of Science ®Google Scholar
• Burchell B , BrierleyCH, RanceD: Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation.Life Sci.57(20), 1819–1831 (1995).
   PubMed Web of Science ®Google Scholar
• King CD , RiosGR, GreenMD, TephlyTR: UDP-glucuronosyltransferases.Curr. Drug Metab.1(2), 143–161 (2000).
   PubMed Web of Science ®Google Scholar
• Knowles SR , ShapiroLE, ShearNH: Anticonvulsant hypersensitivity syndrome, incidence, prevention and management.Drug Saf.21(6), 489–501 (1999).
   PubMed Web of Science ®Google Scholar
• Dieckhaus CM , ThompsonCD, RollerSG, MacdonaldTL: Mechanisms of idiosyncratic drug reactions, the case of felbamate.Chem. Biol. Interact.142(1–2), 99–117 (2002).
   PubMed Web of Science ®Google Scholar
• Uetrecht J : Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.Drug Discov. Today.8(18), 832–837 (2003).
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S , BurkO, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene, multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7), 3473–3478 (2000).
   PubMed Web of Science ®Google Scholar
• Siddiqui A , KerbR, WealeME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med.348(15), 1442–1448 (2003).
   PubMed Web of Science ®Google Scholar
• Zimprich F , Sunder-PlassmannR, StogmannE et al.: Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology63(6), 1087–1089 (2004).
   PubMed Web of Science ®Google Scholar
• Tan NC , HeronSE, SchefferIE et al.: Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology63(6), 1090–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Sills GJ , MohanrajR, ButlerE et al.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia46(5), 643–647 (2005).
   PubMed Web of Science ®Google Scholar
• Kupfer A , PreisigR: Pharmacogenetics of mephenytoin, a new drug hydroxylation polymorphism in man.Eur. J. Clin. Pharmacol.26(6), 753–759 (1984).
   PubMed Web of Science ®Google Scholar
• Brandolese R , ScordoMG, SpinaE, Gusella M, Padrini R: Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.Clin. Pharmacol. Ther.70(4), 391–394 (2001).
   PubMed Web of Science ®Google Scholar
• Ninomiya H , MamiyaK, MatsuoS, IeiriI, HiguchiS, TashiroN: Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.Ther. Drug Monit.22(2), 230–232 (2000).
   PubMed Web of Science ®Google Scholar
• van der Weide J ., Steijns LS, van Weelden MJ, de Haan K: The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics11(4), 287–291 (2001).
   PubMedGoogle Scholar
• Lamba JK , LinYS, SchuetzEG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.54(10), 1271–1294 (2002).
   PubMed Web of Science ®Google Scholar
• Xie HG , KimRB, WoodAJ, SteinCM: Molecular basis of ethnic differences in drug disposition and response.Annu. Rev. Pharmacol. Toxicol.41, 815–850 (2001).
   PubMed Web of Science ®Google Scholar
• Strickler SM , DanskyLV, MillerMA, Seni MH, Andermann E, Spielberg SP: Genetic predisposition to phenytoin-induced birth defects. Lancet2(8458), 746–749 (1985).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SpielbergSP, GrantDM: Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions.Pharmacogenetics4(3), 142–153 (1994).
   PubMedGoogle Scholar
• Green VJ , PirmohamedM, Kitteringham NR et al.: Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem. Pharmacol.50(9), 1353–1359 (1995).
   PubMed Web of Science ®Google Scholar
• Picard F , BertrandS, SteinleinOK, Bertrand D: Mutated nicotinic receptors responsible for autosomal dominant nocturnal frontal lobe epilepsy are more sensitive to carbamazepine. Epilepsia40(9), 1198–1209 (1999).
   PubMed Web of Science ®Google Scholar
• Lucas PT , MeadowsLS, NichollsJ, Ragsdale DS: An epilepsy mutation in the β1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res.64(3), 77–84 (2005).
   PubMed Web of Science ®Google Scholar
• Depondt C : Susceptibility genes in epilepsy and antiepileptic drug responsiveness. PhD Thesis. University of London, UK (2005).
   Google Scholar
• Johnson GC , EspositoL, BarrattBJ et al.: Haplotype tagging for the identification of common disease genes. Nature Genet.29(2), 233–237 (2001).
   PubMed Web of Science ®Google Scholar
• Catterall WA : Molecular mechanisms of gating and drug block of sodium channels. In:Sodium channels and neuronal hyperexcitability. John Wiley & Sons, Ltd, Hoboken, NJ, USA, 206–225 (2002).
   Google Scholar
• Pirmohamed M , LinK, ChadwickD, Park BK: TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology56(7), 890–896 (2001).
   PubMed Web of Science ®Google Scholar
• Chung WH , HungSI, HongHS et al.: Medical genetics, a marker for Stevens-Johnson syndrome. Nature428(6982), 486 (2004).
   PubMed Web of Science ®Google Scholar
• Weinshenker D , SzotP: The role of catecholamines in seizure susceptibility, new results using genetically engineered mice.Pharmacol. Ther.94(3), 213–233 (2002).
   PubMed Web of Science ®Google Scholar
• Szot P , WeinshenkerD, WhiteSS et al.: Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J. Neurosci.19(24), 10985–10992 (1999).
   PubMed Web of Science ®Google Scholar
• Szot P , WeinshenkerD, RhoJM, Storey TW, Schwartzkroin PA: Norepinephrine is required for the anticonvulsant effect of the ketogenic diet. Brain Res. Dev. Brain Res.129(2), 211–214 (2001).
   PubMedGoogle Scholar
• Depondt C , CockHR, HealyDG et al.: The -1021C->T DBH gene variant is not associated with epilepsy or antiepileptic drug response. Neurology63(8), 1497–1499 (2004).
   PubMed Web of Science ®Google Scholar
• Watson JD : The human genome project, past, present, and future.Science248(4951), 44–49 (1990).
   PubMed Web of Science ®Google Scholar
• Gibbs RA , BelmontJW, HardenbolP et al.: The International HapMap Project. Nature426(6968), 789–796 (2003).
   PubMed Web of Science ®Google Scholar
• Wang WY , BarrattBJ, ClaytonDG, Todd JA: Genome-wide association studies, theoretical and practical concerns. Nature Rev. Genet.6(2), 109–118 (2005).
   PubMed Web of Science ®Google Scholar
• Marchini J , DonnellyP, CardonLR: Genome-wide strategies for detecting multiple loci that influence complex diseases.Nature Genet.37(4), 413–417 (2005).
   PubMed Web of Science ®Google Scholar
• Cardon LR , BellJI: Association study designs for complex diseases.Nature Rev. Genet.2(2), 91–99 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein DB : Pharmacogenetics in the laboratory and the clinic.N. Engl. J. Med.348(6), 553–556 (2003).
   PubMed Web of Science ®Google Scholar
• Evans WE , RellingMV: Moving towards individualized medicine with pharmacogenomics.Nature429(6990), 464–468 (2004).
   PubMed Web of Science ®Google Scholar
• Woelderink A , IbarretaD, HopkinsMM, Rodriguez-CerezoE: The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies.Pharmacogenomics J.6(1), 3–7 (2006).
   Google Scholar
• Goldstein DB , TateSK, SisodiyaSM: Pharmacogenetics goes genomic.Nature Rev. Genet.4(12), 937–947 (2003).
   PubMed Web of Science ®Google Scholar
• Perucca E : The spectrum of the new antiepileptic drugs.Acta Neurol. Belg.99(4), 231–238 (1999).
   PubMed Web of Science ®Google Scholar
• Avendano C , MenendezJC: Inhibitors of multidrug resistance to antitumor agents (MDR).Curr. Med. Chem.9(2), 159–193 (2002).
   PubMed Web of Science ®Google Scholar
• Newman MJ , DixonR, ToyonagaB: OC144–093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy.Novartis Found Symp.243, 213–226 (2002).
   PubMedGoogle Scholar
• Summers MA , MooreJL, McAuleyJW: Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy.Ann. Pharmacother.38(10), 1631–1634 (2004).
   PubMed Web of Science ®Google Scholar
• Goldenberg M : Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.Clin. Ther.21(2), 309–318 (1999).
   PubMed Web of Science ®Google Scholar
• Kim SK , WangKC, HongSJ et al.: Gene expression profile analyses of cortical dysplasia by cDNA arrays. Epilepsy Res.56(2–3), 175–183 (2003).
   PubMed Web of Science ®Google Scholar
• Becker AJ , ChenJ, PausS et al.: Transcriptional profiling in human epilepsy, expression array and single cell real-time qRT-PCR analysis reveal distinct cellular gene regulation. Neuroreport13(10), 1327–1333 (2002).
   PubMed Web of Science ®Google Scholar
• Roses AD : Pharmacogenetics and the practice of medicine.Nature405(6788), 857–865 (2000).
   PubMed Web of Science ®Google Scholar
• Roses AD : Pharmacogenetics and drug development, the path to safer and more effective drugs.Nature Rev. Genet.5(9), 645–656 (2004).
   PubMed Web of Science ®Google Scholar
• Jezyk N , LiC, StewartBH, WuX, BockbraderHN, FleisherD: Transport of pregabalin in rat intestine and Caco-2 monolayers.Pharm. Res.16, 519–526 (1999).
   PubMed Web of Science ®Google Scholar
• Kwan P , SillsGJ, BrodieMJ: The mechanisms of action of commonly used antiepileptic drugs.Pharmacol. Ther.90, 21–34 (2001).
   PubMed Web of Science ®Google Scholar

Websites

• NCI GeneCards website. http://nciarray.nci.nih.gov/cards/
   Google Scholar
• Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. www.imm.ki.se/CYPalleles/
   Google Scholar
• NCBI Single Nucleotide Polymorphism website. www.ncbi.nlm.nih.gov/SNP/
   Google Scholar